Opinion on Cardiovascular Diseases in North America

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
Expert View
Expert View

A Mars a day to keep the doctor away?

Mars has unveiled a new product range that claims to satisfy chocolate lovers' cravings while also being good for the heart. With obesity on the rise, and following clampdowns on junk food in US and European schools, entering the health foods market could be a good move. However, Mars is not the only one to realize this, meaning it could face stiff competition.

Published By Datamonitor
16 Sep 2005
Expert View
Expert View

A regulatory irony

Published By Datamonitor
22 Dec 2000
CommentWire
CommentWire

Abbott/Millennium: genomics partnership advances

Obesity is a serious public health concern, costing over $100 billion a year in the US alone, and MLN4760 will complement Abbott's metabolic disease program well. It is also the first fruit of a strategic alliance to develop drugs based on genomic research. Such alliances will become increasingly important in the industry over the next few years.

Published By Datamonitor
28 Nov 2001
CommentWire
CommentWire

Abbott: new coronary stent set for mixed success

Published By Datamonitor
10 Jul 2001
CommentWire
CommentWire

Abiomed: first transplant prompts heart-stopping excitement

Published By Datamonitor
04 Jul 2001
CommentWire
CommentWire

Actelion: FDA endorses first drug

Published By Datamonitor
19 Sep 2001
CommentWire
CommentWire

Actelion: Tracleer approved for pulmonary hypertension

As the first approved oral medication for PAH, the new drug is likely to be popular among treating physicians and enjoy a rapid uptake. However, while Tracleer may improve patients' symptoms, it is a far cry from a cure for PAH, leaving an effective treatment for PAH a major unmet need in the cardiovascular therapeutics market.

Published By Datamonitor
21 Nov 2001
Expert View
Expert View

Acute coronary syndrome: GRAVITAS gives AstraZeneca and Eli Lilly a mandate, but who will cash in?

Results from the GRAVITAS trial suggest that there is no benefit in treating low-risk post-percutaneous coronary intervention patients with high residual platelet activity with a double dose of clopidogrel. The results are not definitive, however: it was a relatively small trial performed in relatively low-risk patients, and may have been insufficiently powered.

Published By Datamonitor
29 Nov 2010
ResearchWire
ResearchWire

Acute stroke: AstraZeneca drug candidate offers blockbuster potential

Published By Datamonitor
31 Aug 2006
CommentWire
CommentWire

Acute stroke: less need for speed with Abbott's Prolyse?

Published By Datamonitor
15 Feb 2001

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.